GSA Capital Partners’s Theriva Biologics TOVX Stock Holding History

GSA Capital Partners’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,101	Closed	-$126K	–	1801
2021 Q3	$126K	Buy	+1,101	New	+$137K	0.01%	1306

Other funds holding TOVX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

GSA Capital Partners's TOVX Position: Q4 2021 in Review

GSA Capital Partners sold out of Theriva Biologics (TOVX) in Q4 2021, closing a stake of 1,101 shares — an estimated $126K sold.

GSA Capital Partners first reported a position in TOVX in Q3 2021 and held it in 1 quarter. The position peaked at $126K in Q3 2021. 33 funds tracked by Wall St. Rank hold TOVX as of Q4 2021.

GSA Capital Partners reported no remaining Theriva Biologics position as of Q4 2021 after selling out during the quarter.
GSA Capital Partners sold 1,101 Theriva Biologics shares in Q4 2021, an estimated $126K.
GSA Capital Partners first reported a position in Theriva Biologics in Q3 2021 and held it in 1 quarter.
GSA Capital Partners's Theriva Biologics position peaked at $126K in Q3 2021.
33 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.